In recent days FARA and Edison Pharmaceuticals have announced that a Phase 2B EPI-743 trial will commence in the very near future. This study will be a six month placebo-controlled, multi centre trial, there will also be a six month extension phase where all subjects will receive EPI-743.
EPI-743 has shown great promise in previous studies where subjects had mitochondrial diseases. Details about study eligibility are available here. Patients with Friedreich’s Ataxia are strongly encouraged to ensure that they are part of a patient registry.